M
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including…
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious inflammatory diseases. The company operates in the healthcare sector, specifically targeting conditions with significant unmet medical needs such as hidradenitis suppurativa and psoriatic arthritis. MoonLake's primary asset is Sonelokimab, a novel therapeutic agent currently undergoing Phase 2 clinical trials. The business model revolves around advancing Sonelokimab through clinical development stages, securing regulatory approvals, and eventually commercializing the drug. Revenue generation is anticipated through partnerships, licensing agreements, and direct sales upon successful market entry. MoonLake serves patients, healthcare providers, and the broader medical community by offering potential new treatment options that aim to improve patient outcomes and quality of life. Key partnerships, such as the development and manufacturing agreement with Vetter Pharma International GmbH, bolster their operational capabilities. The company has also been recognized for its achievements, including winning the European Lifestars Awards for its successful business combination and fundraising efforts.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2021
- Headquarters
- Zug, Switzerland
- Listing
- Public via SPAC 2022
- Employees
- 134
- Open positions
- 8
- Dealroom signal
- 85.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, SPAC Target, SPAC IPO Closed, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $200M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Feb 2026 | $28M | — | Cormorant Asset Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$336M | — |
| 2025 | $0 | — | −$220M | — |
| 2024 | $0 | — | −$142M | — |
| 2023 | $0 | — | −$54M | — |
| 2022 | $0 | — | −$65M | — |
Growth signals
Latest recorded traffic for MoonLake Immunotherapeutics is 12K monthly website visits, up 55.8% over the last three months. MoonLake Immunotherapeutics's team declined 3.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
EMD Performance Materials
Merck KGaA
BVF Partners
Series B and later11 investors entered at this stage
- TMTekla Capital Management
Cormorant Asset Management
RTW Investments- AMAsymmetry capital management
Surveyor Capital- 6C683 Capital
Monashee Investment Management
TCGX- GGGhost Tree Capital Group
- HCHelix Acquisition Corp
Hercules Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MoonLake Immunotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MoonLake Immunotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.